English
Arabic
Français
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Réunionnais
India
Noukoz
BabaShopCenter
Vidéo conférence
Runsound music
Films partner IMDb
Affiliation
Prêts Immobiliers
The report "Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV), By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes, Others) - Global Forecasts to 2030"
The global prostate cancer diagnostic market is projected to reach USD 126.5 billion in 2023, registering a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period 2024-2030. The growth of the market is majorly driven by the innovation in drugs and developments in genomics and proteomics
Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=22416
Competitive Dashboard:
The prominent key players operating in the global prostate cancer diagnostic market are Accuquik Test Kits (U.S.), ACON Laboratories, Inc. (U.S.), bioMérieux SA (France), HUMASIS (South Korea), Teco Diagnostics (U.S.), Hologic Inc. (U.S.), MDxHealthcare (Belgium), Abbott (U.S.), Siemens Healthcare GmbH (Germany), OPKO Health Inc. (U.S.), Myriad Genetics, Inc. (U.S.), DiaSorin S.p.A (Italy), Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.), Metamark Genetics, Inc. (U.S.), Prostatype Genomics (Switzerland), Fujirebio (Belgium), Proteomedix (Switzerland), Eurolyser Diagnostica GmbH (Austria), F. Hoffmann-La Roche Ltd (Switzerland)
The global prostate cancer diagnostic market is projected to reach USD 126.5 billion in 2023, registering a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period 2024-2030. The growth of the market is majorly driven by the innovation in drugs and developments in genomics and proteomics
Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=22416
Competitive Dashboard:
The prominent key players operating in the global prostate cancer diagnostic market are Accuquik Test Kits (U.S.), ACON Laboratories, Inc. (U.S.), bioMérieux SA (France), HUMASIS (South Korea), Teco Diagnostics (U.S.), Hologic Inc. (U.S.), MDxHealthcare (Belgium), Abbott (U.S.), Siemens Healthcare GmbH (Germany), OPKO Health Inc. (U.S.), Myriad Genetics, Inc. (U.S.), DiaSorin S.p.A (Italy), Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.), Metamark Genetics, Inc. (U.S.), Prostatype Genomics (Switzerland), Fujirebio (Belgium), Proteomedix (Switzerland), Eurolyser Diagnostica GmbH (Austria), F. Hoffmann-La Roche Ltd (Switzerland)
The report "Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV), By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes, Others) - Global Forecasts to 2030"
The global prostate cancer diagnostic market is projected to reach USD 126.5 billion in 2023, registering a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period 2024-2030. The growth of the market is majorly driven by the innovation in drugs and developments in genomics and proteomics
Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=22416
Competitive Dashboard:
The prominent key players operating in the global prostate cancer diagnostic market are Accuquik Test Kits (U.S.), ACON Laboratories, Inc. (U.S.), bioMérieux SA (France), HUMASIS (South Korea), Teco Diagnostics (U.S.), Hologic Inc. (U.S.), MDxHealthcare (Belgium), Abbott (U.S.), Siemens Healthcare GmbH (Germany), OPKO Health Inc. (U.S.), Myriad Genetics, Inc. (U.S.), DiaSorin S.p.A (Italy), Beckman Coulter, Inc. (a subsidiary of Danaher) (U.S.), Metamark Genetics, Inc. (U.S.), Prostatype Genomics (Switzerland), Fujirebio (Belgium), Proteomedix (Switzerland), Eurolyser Diagnostica GmbH (Austria), F. Hoffmann-La Roche Ltd (Switzerland)
·1K Views
·0 Vista previa
